Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Crizotinib-induced immunogenic cell death in non-small cell lung cancer.
Liu P, Zhao L, Pol J, Levesque S, Petrazzuolo A, Pfirschke C, Engblom C, Rickelt S, Yamazaki T, Iribarren K, Senovilla L, Bezu L, Vacchelli E, Sica V, Melis A, Martin T, Xia L, Yang H, Li Q, Chen J, Durand S, Aprahamian F, Lefevre D, Broutin S, Paci A, Bongers A, Minard-Colin V, Tartour E, Zitvogel L, Apetoh L, Ma Y, Pittet MJ, Kepp O, Kroemer G. Liu P, et al. Among authors: iribarren k. Nat Commun. 2019 Apr 2;10(1):1486. doi: 10.1038/s41467-019-09415-3. Nat Commun. 2019. PMID: 30940805 Free PMC article.
eIF2α phosphorylation is pathognomonic for immunogenic cell death.
Bezu L, Sauvat A, Humeau J, Gomes-da-Silva LC, Iribarren K, Forveille S, Garcia P, Zhao L, Liu P, Zitvogel L, Senovilla L, Kepp O, Kroemer G. Bezu L, et al. Among authors: iribarren k. Cell Death Differ. 2018 Aug;25(8):1375-1393. doi: 10.1038/s41418-017-0044-9. Epub 2018 Jan 22. Cell Death Differ. 2018. PMID: 29358668 Free PMC article.
Author Correction: Crizotinib-induced immunogenic cell death in non-small cell lung cancer.
Liu P, Zhao L, Pol J, Levesque S, Petrazzuolo A, Pfirschke C, Engblom C, Rickelt S, Yamazaki T, Iribarren K, Senovilla L, Bezu L, Vacchelli E, Sica V, Melis A, Martin T, Xia L, Yang H, Li Q, Chen J, Durand S, Aprahamian F, Lefevre D, Broutin S, Paci A, Bongers A, Minard-Colin V, Tartour E, Zitvogel L, Apetoh L, Ma Y, Pittet MJ, Kepp O, Kroemer G. Liu P, et al. Among authors: iribarren k. Nat Commun. 2019 Apr 17;10(1):1883. doi: 10.1038/s41467-019-09838-y. Nat Commun. 2019. PMID: 30996258 Free PMC article.
Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.
Buqué A, Bloy N, Perez-Lanzón M, Iribarren K, Humeau J, Pol JG, Levesque S, Mondragon L, Yamazaki T, Sato A, Aranda F, Durand S, Boissonnas A, Fucikova J, Senovilla L, Enot D, Hensler M, Kremer M, Stoll G, Hu Y, Massa C, Formenti SC, Seliger B, Elemento O, Spisek R, André F, Zitvogel L, Delaloge S, Kroemer G, Galluzzi L. Buqué A, et al. Among authors: iribarren k. Nat Commun. 2020 Jul 30;11(1):3819. doi: 10.1038/s41467-020-17644-0. Nat Commun. 2020. PMID: 32732875 Free PMC article.
The oncolytic compound LTX-401 targets the Golgi apparatus.
Zhou H, Sauvat A, Gomes-da-Silva LC, Durand S, Forveille S, Iribarren K, Yamazaki T, Souquere S, Bezu L, Müller K, Leduc M, Liu P, Zhao L, Marabelle A, Zitvogel L, Rekdal Ø, Kepp O, Kroemer G. Zhou H, et al. Among authors: iribarren k. Cell Death Differ. 2016 Dec;23(12):2031-2041. doi: 10.1038/cdd.2016.86. Epub 2016 Sep 2. Cell Death Differ. 2016. PMID: 27588704 Free PMC article.
Anticancer effects of anti-CD47 immunotherapy in vivo.
Iribarren K, Buque A, Mondragon L, Xie W, Lévesque S, Pol J, Zitvogel L, Kepp O, Kroemer G. Iribarren K, et al. Oncoimmunology. 2018 Dec 11;8(3):1550619. doi: 10.1080/2162402X.2018.1550619. eCollection 2019. Oncoimmunology. 2018. PMID: 30723582 Free PMC article.
Identification of pharmacological agents that induce HMGB1 release.
Liu P, Zhao L, Loos F, Iribarren K, Lachkar S, Zhou H, Gomes-da-Silva LC, Chen G, Bezu L, Boncompain G, Perez F, Zitvogel L, Kepp O, Kroemer G. Liu P, et al. Among authors: iribarren k. Sci Rep. 2017 Nov 2;7(1):14915. doi: 10.1038/s41598-017-14848-1. Sci Rep. 2017. PMID: 29097772 Free PMC article.
Publisher Correction: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.
Buqué A, Bloy N, Perez-Lanzón M, Iribarren K, Humeau J, Pol JG, Levesque S, Mondragon L, Yamazaki T, Sato A, Aranda F, Durand S, Boissonnas A, Fucikova J, Senovilla L, Enot D, Hensler M, Kremer M, Stoll G, Hu Y, Massa C, Formenti SC, Seliger B, Elemento O, Spisek R, André F, Zitvogel L, Delaloge S, Kroemer G, Galluzzi L. Buqué A, et al. Among authors: iribarren k. Nat Commun. 2020 Sep 17;11(1):4787. doi: 10.1038/s41467-020-18719-8. Nat Commun. 2020. PMID: 32943636 Free PMC article.
Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity.
Xie W, Forveille S, Iribarren K, Sauvat A, Senovilla L, Wang Y, Humeau J, Perez-Lanzon M, Zhou H, Martínez-Leal JF, Kroemer G, Kepp O. Xie W, et al. Among authors: iribarren k. Oncoimmunology. 2019 Sep 5;8(11):e1656502. doi: 10.1080/2162402X.2019.1656502. eCollection 2019. Oncoimmunology. 2019. PMID: 31646106 Free PMC article.
26 results